<DOC>
	<DOCNO>NCT00966992</DOCNO>
	<brief_summary>The treatment cervical cancer chemotherapy radiation make woman post menopausal ( estrogen ovary ) , woman already menopause . Estrogen play key role maintain bone health . Therefore , woman high risk get osteoporosis ( decrease mineral bone ) bone fracture . The overall purpose research look effect zoledronic acid ( Zometa ) prevent bone loss . Studies also show zoledronic acid may prevent metastasis bone occur woman cervical cancer . Zometa investigational ( approve Food Drug Administration ( FDA ) ) study prevent metastasis bone woman cervical cancer . Therefore , goal study also look effect zoledronic acid ( Zometa ) circulate tumor cell bone marrow blood . This study do find way prevent bone loss metastasis bone woman undergo chemotherapy radiation cervical cancer . An additional component study assess importance stress immune marker blood standard treatment .</brief_summary>
	<brief_title>Study Zoledronic Acid Versus Observation Bone Mineral Density Incidence Micrometastasis Women Undergoing Pelvic Radiation Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES - To determine incidence disseminate tumor cell ( DTCs ) bone marrow circulate tumor cell ( CTCs ) blood woman cervical cancer diagnosis 3 9 month chemotherapy pelvic radiation without Zometa . - To determine change biochemical marker bone turnover diagnosis 9 month radiation woman receive chemoradiation cervical cancer without Zometa . - To determine change bone mineral density diagnosis 9 month chemoradiation without Zometa . - To determine depressed anxious mood associate great impairment adaptive immunity ( ratio Th1/Th2 ) high level angiogenesis ( VEGF ) peripheral blood cervical cancer patient . - To examine relationship standardized uptake value ( SUV ) Max metabolic heterogeneity primary tumor evidence persistent/recurrent disease 3 9 month Fludeoxyglucose ( FDG ) -Positron Emission Tomography ( PET ) scan DTCs CTCs .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasm Micrometastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Histologically proven squamous , adenosquamous adenocarcinoma International Federation Gynecology Obstetrics ( FIGO ) Stage IBIVA uterine cervix undergo initial radiation cisplatin base chemotherapy primary treatment . Gynecologic Oncology Group performance status 0 , 1 , 2 . Patients ureteral obstruction must undergo stent placement nephrostomy tube placement prior study entry . Age &gt; = 18 year . Patients must sign informed consent . Patients must adequate : Bone marrow function : absolute neutrophil count ( ANC ) great equal 1,500/ul , equivalent Common Toxicity Criteria ( CTCAE ) grade 1 . Platelets great equal 100,000/ul . Renal function : creatinine le equal 1.5 x institutional upper limit normal ( ULN ) . If creatinine great 1.5 x ULN , creatinine clearance must great 60 ml/min . Hepatic function : bilirubin le equal 1.5 x ULN . AST alkaline phosphatase less equal 2.5 x ULN . Neurologic function : neuropathy ( sensory motor ) less equal CTCAE grade 1 . Coagulation : prothrombin time ( PT ) international normalize ratio ( INR ) &lt; 1.5 ( INR may 2 3 patient stable dose therapeutic warfarin ) PTT &lt; 1.2 time control . Evidence sepsis severe infection . Previous current treatment osteoporosis . Patients denovo osteoporosis also exclude . Evidence bone metastasis . Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g. , extraction , implant ) . Patients history invasive malignancy ( treatment within last 5 year ) nonmelanoma skin cancer . Patients know hypersensitivity Zometa bisphosphonates . Patients pregnant breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Uterine Cervical Cancer</keyword>
	<keyword>Cancer Cervix</keyword>
	<keyword>Cervix Cancer</keyword>
</DOC>